Published in AIDS Weekly, January 31st, 2000
"Previous studies have demonstrated that nasal absorption of tyrosine and tyrosine linked model compounds is by a carrier-mediated mechanism," wrote C. Yang and colleagues from the University of Missouri. "The objective of this study is to optimize nasal delivery of AZT via tyrosine linked prodrug approach."
Yang et al. presented their study at the 1999 Annual Meeting of the American Association for Pharmaceutical Scientists, held November 14-18, 1999, in New Orleans, Louisiana.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.